Unipril is an antihypertensive medication containing ramipril that is presented as a treatment for hypertension, congestive heart failure, reducing cardiovascular risk, and proteinuric nephropathy. It works by inhibiting the angiotensin converting enzyme, thereby reducing blood pressure. Studies show Unipril reduces cardiovascular events in high-risk patients, provides the highest survival rate among ACE inhibitors for heart attack patients, and offers beneficial effects for diabetic patients by reducing cardiovascular death and events. It also effectively improves parameters in chronic nephropathy and eliminates the need for dialysis with long-term use.

1. Welcome to the Session of
Unipril
(Ramipril BP 2.5 & 5)
Presented by
Mohammed Moshiur Rahaman
Brand Executive
Brand Management Department
The ACME Laboratories Ltd.

2. Product Information
 Brand Name : Unipril 2.5 & 5
 Composition : Ramipril BP 2.5 & 5
 Therapeutic group : Antihypertensive (ACE inhibitor)
 Product group :
 Pack Size : 3 X10’s
 Unit Price : 5.01 tk/unit (2.5 mg) tablet
8.04 tk/unit (5 mg) tablet

3. Mechanism of Action
Unipril inhibits conversion of Angiotensin I to
Angiotensin II by inhibiting Angiotensin converting
Enzyme (ACE).

4. Angiotensinogen (from the liver)
Renin from Kidney
Angiotensin I
ACE enzyme
No production of Angiotensin II
Blood pressure decreases
Unipril inhibits
ACE enzyme

6. Market Information:
The market size of Ramipril is 22 crore (appr.) with Growth 15.9%.
Brand Company Sales value(crore)
yearly
Ramoril Incepta 7.92
Ramace Opsonin 3.32
Tritace Sanofi Aventis 2.91
Ripril Square 1.50
Piramil Sandoz 1.41

7. Indications
 Mild to severe hypertension, where it may be used alone
or in combination with thiazide diuretics.
 Congestive heart failure
 To reduce the risk of stroke, myocardial infarction and
death from cardiovascular events in patients with a
history of cardiovascular diseases
 Proteinuric non-diabetic nephropathy

8. Unipril reduces CV events in high risk patients
According to HOPE study, Ramipril significantly reduces the rate of death, myocardial
infarction and stroke in a broad range of high risk patients who are not known to have a
low ejection fraction or heart failure.
…..An appropriate choice for CV
patients

9. Unipril shows the highest survival rate among all ACE
inhibitors
After the incidence of acute MI, patients were treated with different ACE
inhibitors. Ramipril shows significant lower mortality than other ACE
inhibitors.
……Better for MI patients

10. Unipril offers beneficial effects in people with diabetic
patients
According to MICRO-HOPE study, Ramipril significantly reduces the
cardiovascular death, stroke and heart attack in patients with diabetes.
……A perfect choice for diabetic
patients

11. Unipril provides effective improvement of all
parameters in Chronic Nephropathy
According to REIN study, in patient with chronic nephropathy & high risk of
rapid progression of ESRD, Ramipril reversed the tendency of GFR to decline
with time. Moreover, a treatment period of sufficient duration (≥36 months )
eliminated the need for dialysis.
……shows effective and consistent renoprotective effect

12. Use In Pregnancy And Lactation
Pregnancy
Pregnancy should be excluded before start of treatment with
Ramipril and avoided during treatment. However, if
pregnancy is detected, Unipril (Ramipril) should be
discontinued as early as possible unless continued use is
considered life saving.
Lactation
Ramipril should not be used during lactation.

13. Target Doctors
 Cardiologist
 Neurologist
 Medicine specialist
 General practitioners
 Hospital practitioners

14. Highlighting Points
Unipril…
 is an appropriate choice for CV patients
 prevents premature death in acute MI
 reduces the atherosclerosis progression
 offers beneficial effects in diabetic patients
 ensures effective renal protection
 shows better tolerability

16. Thank you all